D-Dimer Trends Predict Recurrent Stroke in Patients with Cancer-Related Hypercoagulability

Cerebrovasc Dis Extra. 2024;14(1):9-15. doi: 10.1159/000535644. Epub 2023 Dec 7.

Abstract

Introduction: In patients with cancer-associated hypercoagulability (CAH)-related stroke, D-dimer trends after anticoagulant therapy may offer a biomarker of treatment efficacy. The purpose of this study was to clarify the association between D-dimer trends and recurrent stroke after anticoagulant therapy in patients with CAH-related stroke.

Methods: We performed retrospective cohort study of consecutive patients with CAH-related stroke at two stroke centers from 2011 to 2020. The ratio of posttreatment to pretreatment D-dimer levels (post/pre ratio) was used as an indicator of D-dimer trends after anticoagulant therapy. Fine-Gray models were used to evaluate the association between post/pre ratio and recurrent stroke.

Results: Among 360 acute ischemic stroke patients with active cancer, 73 patients with CAH-related stroke were included in this study. Recurrent stroke occurred in 13 patients (18%) during a median follow-up time of 28 days (interquartile range, 11-65 days). Multivariate analysis revealed that high post/pre ratio was independently associated with recurrent stroke (per 0.1 increase: hazard ratio 2.20, 95% confidence interval 1.61-3.01, p = 0.012).

Conclusion: D-dimer levels after anticoagulant therapy were associated with recurrent stroke in CAH-related stroke patients. Patients with neutral trends in high D-dimer levels after anticoagulant therapy were at high risk of recurrent stroke.

Keywords: Cancer-related stroke; D-dimer; Hypercoagulability; Trousseau syndrome.

MeSH terms

  • Anticoagulants / adverse effects
  • Cerebral Infarction
  • Fibrin Fibrinogen Degradation Products / analysis
  • Humans
  • Ischemic Stroke* / complications
  • Neoplasms* / complications
  • Neoplasms* / diagnosis
  • Neoplasms* / drug therapy
  • Retrospective Studies
  • Risk Factors
  • Stroke* / complications
  • Stroke* / diagnosis
  • Stroke* / epidemiology
  • Thrombophilia* / complications
  • Thrombophilia* / diagnosis
  • Thrombophilia* / drug therapy

Substances

  • fibrin fragment D
  • Fibrin Fibrinogen Degradation Products
  • Anticoagulants

Grants and funding

This study has no any corporate sponsorship, government funding, and institutional funding.